Maximum quantity allowed is 999
Please select the quantity
CAS RN: 184475-35-2 | Product Number: G0546
Gefitinib
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days |
|---|---|---|---|
| 1G |
₩146,200
|
25 | ≥60 |
| 5G |
₩497,700
|
22 | 2 |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
| Product Number | G0546 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__2H__2__4ClFN__4O__3 = 446.91 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 184475-35-2 |
| Reaxys Registry Number | 8949523 |
| PubChem Substance ID | 468591928 |
| MDL Number | MFCD04307832 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 194.0 to 198.0 °C |
Properties (reference)
| Melting Point | 196 °C |
| Maximum Absorption Wavelength | 332 nm |
| Solubility in water | Insoluble |
| Solubility (slightly sol. in) | Tetrahydrofuran |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H315 : Causes skin irritation. H319 : Causes serious eye irritation. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. H351 : Suspected of causing cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | VA0952000 |
Transport Information:
| H.S.code* | 2934.99-000 |
Application
Gefitinib: A Potent and Selective Inhibitor of EGFR Tyrosine Kinase
The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), is expressed on the cell surface of both normal and cancer cells and plays a role in the processes of cell growth and proliferation. It is reported that gefitinib (ZD1839) is a potent and selective inhibitor of EGFR tyrosine kinase (EGFRTK). In vitro, gefitinib arrests the cell cycle at G1 phase by inducing intrinsic cyclin-dependent kinase (cdk) inhibitors. Furthermore, gefitinib inhibits vascular endothelial growth factor (VEGF) production in tumor cells through inhibition of EGFR signaling, leading to suppression of angiogenesis. For your reference, [C3647] and [H1606] are key synthetic intermediates of gefitinib. (The product is for research purpose only.)
References
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions (a review)
- Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry
- A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.